Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination formulation containing lidocaine, dexamethasone, and honey. Lidocaine is an amide-type local anesthetic that blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction and providing local anesthesia. Dexamethasone is a synthetic glucocorticoid corticosteroid with potent anti-inflammatory and immunosuppressant properties; it acts by binding to the glucocorticoid receptor and modulating gene expression to suppress inflammatory mediators. Honey has natural antimicrobial, anti-inflammatory, and wound-healing properties due to its high osmolarity, hydrogen peroxide content, and bioactive compounds. This combination may be used topically or as an oral rinse for symptomatic relief of pain (such as oral mucositis), inflammation reduction, or wound healing in various clinical settings[1][3][6]. The addition of lidocaine provides rapid pain relief through local anesthesia; dexamethasone reduces inflammation; honey supports mucosal healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + dexamethasone + honey.